Business Context and Reporting Period
This Form 8-K Current Report was filed by Spruce Biosciences, Inc. on May 22, 2023, regarding corporate governance changes effective May 25, 2023. The company is incorporated in Delaware and its common stock trades on the Nasdaq Global Select Market under the symbol SPRB.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The primary material change reported is the resignation of Dina Chaya, Ph.D., C.F.A., from the Board of Directors and her roles on the Nominating and Corporate Governance Committee and the Audit Committee. The resignation was not the result of any dispute with the Company.
Outlook, Management Commentary, and Compensation
The Board appointed new directors to fill the vacancies created by Dr. Chaya's resignation:
- Percival Barretto-Ko: Appointed to the Board as a Class II Director (term expires at the 2025 Annual Meeting) and to the Audit Committee.
- Compensation: Annual cash retainer of $40,000 for director service and $7,500 for Audit Committee service (pro-rated for 2023).
- Equity: Granted a nonstatutory stock option to purchase 60,000 shares, vesting monthly over three years. Eligible for future annual options of 30,000 shares commencing with the 2024 Annual Meeting.
- Daniel Spiegelman: Appointed to the Nominating Committee.
- Compensation: Annual cash retainer of $4,000 (pro-rated for 2023).
- Kirk Ways, M.D., Ph.D.: Appointed as Chair of the Nominating Committee.
- Compensation: Annual cash retainer of $8,000 (pro-rated for 2023).
There are no related person transactions or unusual items disclosed in this filing.
Key Facts for Investor Verification
- Verify the effective date of the board composition changes (May 25, 2023).
- Confirm the vesting schedule and terms of the 60,000-share stock option granted to Percival Barretto-Ko.
- Review the Company's Non-Employee Director Compensation Policy to understand the pro-rated cash retainers for 2023.
- Note that the resignation of Dr. Chaya was not due to any disagreement regarding operations or policies.